Global

Some 156 nations have joined a global scheme for fair distribution of future vaccines against COVID-19, an alliance led by the World Health Organization (WHO).

If the coronavirus vaccines currently being tested don't pan out, don't expect new drugs to fill the gap any time soon.

Developing an effective vaccine is the first step. Then comes the question of how to deliver hundreds of millions of doses that may need to be kept at arctic temperatures.

As government and private money pour into the global race for a Covid-19 vaccine, drugmakers are under great pressure to keep the shot affordable while also keeping investors happy.

Contributions Of Public Health, Pharmaceuticals, And Other Medical Care To US Life Expectancy Changes, 1990-2015

How a Monopoly on Remdesivir Led to Rationing

Adopting a through-cycle approach to deal making in the wake of the COVID-19 pandemic can position pharmaceutical companies for greater success in the next normal.

Countries should join the World Health Organization's (WHO) COVAX vaccine facility by a Friday deadline to help ensure that immunizations are fairly and efficiently distributed.

Valuations are fundamental information about any startup.

Researchers say drug companies need to be more open about how vaccine trials are run to reassure Americans who are skittish about getting a coronavirus vaccine.

One of the leading efforts to find a coronavirus vaccine has run into difficulty, as AstraZeneca temporarily halted trials.

RAND senior analyst Sonja Marjanovic explains how changes in society have brought about opportunities for the pharmaceutical industry to innovate to better meet the needs of patients and health care systems.

Evolution of the COVID-19 vaccine development landscape.

Several vaccines are currently in large-scale studies to see if they can prevent COVID-19, and more are on the way.

The statement is meant to reassure the public that the companies will not seek a premature approval of vaccines under pressure from the Trump administration.